Dolutegravir in Pregnant HIV Mothers and Their Neonates
Status:
Active, not recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
To evaluate dolutegravir (DTG) efficacy in women who present with untreated HIV in late
pregnancy.
An open-label, multi-centre randomised controlled trial of DTG vs efavirenz-based regimens
for women commencing cART in late pregnancy. HIV positive pregnant women presenting with
untreated HIV infection in late (≥28 weeks gestation) pregnancy will be randomised 1:1 to
receive DTG (50mg once daily) + 2 nucleoside reverse transcriptase inhibitors (NRTIs) or EFV
+ 2 NRTIs (SoC)
Phase:
Phase 3
Details
Lead Sponsor:
University of Liverpool
Collaborators:
Infectious Diseases Institute, Uganda Liverpool School of Tropical Medicine Radboud University UNITAID University of Cape Town